{"id":"comparator-glimepiride","safety":{"commonSideEffects":[{"rate":"5–15","effect":"Hypoglycemia"},{"rate":"2–5","effect":"Weight gain"},{"rate":"1–3","effect":"Dizziness"},{"rate":"1–3","effect":"Headache"},{"rate":"1–2","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1481","moleculeType":"Small molecule","molecularWeight":"490.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glimepiride is a meglitinide-class sulfonylurea that closes ATP-sensitive potassium channels in pancreatic beta cells, leading to cell depolarization and calcium influx, which triggers insulin release. This mechanism helps lower blood glucose in patients with type 2 diabetes by increasing endogenous insulin secretion.","oneSentence":"Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:19:41.317Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07365358","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2026-03","conditions":"Diabete Type 2","enrollment":200},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT01951339","phase":"NA","title":"Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2013-10","conditions":"Type 2 Diabetes, Cardiovascular Disease","enrollment":36},{"nctId":"NCT01131182","phase":"PHASE4","title":"Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-13","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":1147},{"nctId":"NCT02769481","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-08-15","conditions":"Type 2 Diabetes Mellitus","enrollment":426},{"nctId":"NCT02973477","phase":"PHASE4","title":"Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2017-01-12","conditions":"Type2 Diabetes, Cardiovascular Diseases","enrollment":45},{"nctId":"NCT02964572","phase":"NA","title":"Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-11","conditions":"Type2 Diabetes Mellitus","enrollment":61},{"nctId":"NCT01999218","phase":"PHASE3","title":"Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":1326},{"nctId":"NCT03060980","phase":"PHASE3","title":"Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin","status":"TERMINATED","sponsor":"Intarcia Therapeutics","startDate":"2017-03-03","conditions":"Diabetes Mellitus, Type 2","enrollment":245},{"nctId":"NCT00993187","phase":"PHASE4","title":"Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-04","conditions":"Type 2 Diabetes Mellitus","enrollment":292},{"nctId":"NCT01177384","phase":"PHASE3","title":"Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-25","conditions":"Type 2 Diabetes Mellitus","enrollment":380},{"nctId":"NCT01076075","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-03","conditions":"Type 2 Diabetes Mellitus","enrollment":427},{"nctId":"NCT00701090","phase":"PHASE3","title":"A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-05","conditions":"Type 2 Diabetes Mellitus, Non Insulin Dependent, Diabetes Mellitus, Non-Insulin-Dependent","enrollment":1035},{"nctId":"NCT01425580","phase":"PHASE2","title":"Liraglutide and Heart Failure in Type 2 Diabetes","status":"COMPLETED","sponsor":"Thomas Nystrom","startDate":"2012-01","conditions":"Congestive Heart Failure, Type 2 Diabetes Mellitus","enrollment":62},{"nctId":"NCT02106104","phase":"PHASE4","title":"Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2014-03","conditions":"Type 2 Diabetes","enrollment":48},{"nctId":"NCT00106704","phase":"PHASE3","title":"Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Diabetes Mellitus, Type 2","enrollment":441},{"nctId":"NCT02426294","phase":"PHASE4","title":"Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin","status":"UNKNOWN","sponsor":"Pusan National University Hospital","startDate":"2015-02","conditions":"Type 2 Diabetes Mellitus","enrollment":154},{"nctId":"NCT00740051","phase":"PHASE3","title":"A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-08","conditions":"Diabetes Mellitus, Type 2","enrollment":227},{"nctId":"NCT01341717","phase":"PHASE4","title":"Effects of Sitagliptin on Type 2 Diabetes Mellitus Patients on Treatment With Metformin and Insulin","status":"COMPLETED","sponsor":"Jothydev's Diabetes and Research Centre","startDate":"2012-02","conditions":"Diabetes Mellitus, Type 2","enrollment":440},{"nctId":"NCT01699737","phase":"PHASE2","title":"Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Akros Pharma Inc.","startDate":"2012-09","conditions":"Type 2 Diabetes Mellitus","enrollment":325},{"nctId":"NCT01819402","phase":"NA","title":"Pioglitazone Decreases Visceral Fat Metabolism","status":"UNKNOWN","sponsor":"Kurume University","startDate":"2012-03","conditions":"To Evaluate the Effect of Pioglitazone on Glucose Metabolism of Fat Tissue by Using FDG-PET/CT Imaging","enrollment":60},{"nctId":"NCT01455883","phase":"PHASE3","title":"A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes","status":"WITHDRAWN","sponsor":"Intarcia Therapeutics","startDate":"2013-02","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT01455922","phase":"PHASE3","title":"A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes","status":"WITHDRAWN","sponsor":"Intarcia Therapeutics","startDate":"2013-02","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT00225264","phase":"PHASE3","title":"Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.","status":"COMPLETED","sponsor":"Takeda","startDate":"2003-10","conditions":"Diabetes Mellitus","enrollment":458},{"nctId":"NCT00225277","phase":"PHASE3","title":"Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2003-07","conditions":"Diabetes Mellitus","enrollment":547}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Amaryl®"],"phase":"marketed","status":"active","brandName":"Comparator: glimepiride","genericName":"Comparator: glimepiride","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}